Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial
Journal of Primary Care & Community Health · 2025
DOI: 10.1177/21501319251330622 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Primary Care & Community Health, 2025. Verfasst von Anmol Desai und 9 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas at Austin Dell Medical School, Austin, TX, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Vulnerable Populations, Workflow. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Introduction
Hepatitis C virus (HCV) treatment with pan-genotypic direct acting antivirals is highly effective, given an evidence-based simplified treatment algorithm. Yet access to treatment is limited among vulnerable populations.
Objective
We assessed the effectiveness of site-specific HCV treatment workflows on HCV care for vulnerable populations in Austin, Texas.
Methods
Patients diagnosed with chronic hepatitis C enrolled in care at a study site were eligible for this prospective, single-arm clinical trial. We assessed the proportion of participants that: (1) were prescribed treatment, (2) initiated treatment, (3) completed treatment, (4) were assessed for cure, and (5) achieved cure. We also evaluated implementation using the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework.
Results
Of 62 participants, 89% had ever experienced homelessness and 94% had ever used drugs. An estimated 66% (95% CrI, 42%-84%) were prescribed treatment and 49% (95% CrI, 26%-70%) initiated treatment. An estimated 38% (95% CrI, 20%-58%) completed treatment, 14% (95% CrI, 4%-44%) were assessed for cure, and 10% (95% CrI, 2%-35%) achieved cure.
Conclusions
We identified gaps along the HCV care cascade between: (1) enrolled to prescribed treatment and (2) completed treatment to assessed for cure. Site-specific HCV treatment workflows were insufficient to engage participants in care and avoid treatment delays. Novel approaches are needed and these may include patient outreach, patient navigation, test-and-treat protocols, and removing financial or payor barriers to medication access. Trial Registration: Registered on ClinicalTrials.gov on July, 14, 2022. Identifier: NCT05460130. https://clinicaltrials.gov/ct2/show/NCT05460130 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Texas at Austin Dell Medical School, Austin, TX, USA.
- CommUnityCare, Austin, TX, USA.
- Central Health, Austin, TX, USA.
ORCID-Profile: Anmol Desai, Cristal Brown, Tim Mercer, Darlene Bhavnani
Förderung
- Gilead Sciences
Zitieren
APA
Desai, A., Reinis, K., O'Neal, L., Chang, P., Brown, C., Stefanowicz, M., Kuang, A., Agrawal, D., Mercer, T., & Bhavnani, D. (2025). Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial. Journal of Primary Care & Community Health. https://doi.org/10.1177/21501319251330622
Vancouver
Desai A, Reinis K, O'Neal L, Chang P, Brown C, Stefanowicz M, et al. Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial. Journal of Primary Care & Community Health. 2025. doi:10.1177/21501319251330622
BibTeX
@article{Desai2025,
author = {Desai, Anmol and Reinis, Kia and O'Neal, Lauren and Chang, Patrick and Brown, Cristal and Stefanowicz, Michael and Kuang, Audrey and Agrawal, Deepak and Mercer, Tim and Bhavnani, Darlene},
title = {Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial},
journal = {Journal of Primary Care & Community Health},
year = {2025},
doi = {10.1177/21501319251330622}
}
EUVIMED